KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Cost of Revenue: 2017-2024

Historic Cost of Revenue for BioNTech SE (BNTX) over the last 8 years, with Dec 2024 value amounting to $578.4 million.

  • BioNTech SE's Cost of Revenue fell 11.76% to $173.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $608.2 million, marking a year-over-year increase of 17.47%. This contributed to the annual value of $578.4 million for FY2024, which is 10.37% down from last year.
  • According to the latest figures from FY2024, BioNTech SE's Cost of Revenue is $578.4 million, which was down 10.37% from $645.3 million recorded in FY2023.
  • BioNTech SE's 5-year Cost of Revenue high stood at $3.3 billion for FY2021, and its period low was $70.7 million during FY2020.
  • In the last 3 years, BioNTech SE's Cost of Revenue had a median value of $645.3 million in 2023 and averaged $1.4 billion.
  • In the last 5 years, BioNTech SE's Cost of Revenue soared by 4,610.81% in 2021 and then plummeted by 78.88% in 2023.
  • BioNTech SE's Cost of Revenue (Yearly) stood at $70.7 million in 2020, then spiked by 4,610.81% to $3.3 billion in 2021, then dropped by 8.26% to $3.1 billion in 2022, then slumped by 78.88% to $645.3 million in 2023, then decreased by 10.37% to $578.4 million in 2024.